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ORIGINAL ARTICLE
Osteogenesis imperfecta (OI) (MIM 166200,
166210, 259420 and 166220) is a congenital dis-
order characterized by increased bone fragility, low
bone mass, and other connective-tissue manifes-
tations. It is estimated to affect 1 in 15,000 to 
1 in 25,000 individuals.1,2 There are a variety of
extra-skeletal manifestations associated with this
disorder, including blue sclera, dentinogenesis
imperfecta (DI), hearing loss, and hyperlaxity of
ligaments and skin.3 Most patients have muta-
tions in the COL1A1 or COL1A2 genes localized
on chromosomes 17 and 7, respectively.4 The most
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Background/Purpose: Osteogenesis imperfecta (OI) (MIM 166200, 166210, 259420 and 166220) is a
congenital disorder characterized by increased bone fragility and low bone mass. Information regarding the
clinical features of this genetic disorder is lacking in Taiwan. This study aimed to characterize the clinical
features of OI patients in Taiwan to establish a practical correlation for distinguishing different clinical
subtypes of the disorder.
Methods: A review of medical records identified 48 patients with OI (33 female and 15 male; age range, 
2 months to 53 years) from January 1996 to June 2008. Diagnosis and classification, using the classifi-
cation system outlined by Sillence et al, were based on clinical and radiological characteristics. We also 
analyzed the clinical presentation, physical examination and bone mineral density (BMD) among the 
different subtypes of OI.
Results: Retrospective analysis of the medical records revealed that 48 OI patients could be classified into
types I (n = 19), III (n = 10), and IV (n = 19). There were statistically significant differences between these
three types in terms of height, weight, BMD, dentinogenesis imperfecta, bone deformity, scoliosis, walking
ability, annual fracture rate, and family history. However, no significant differences were noted for blue
sclera (p = 0.075) and hearing loss (p = 0.832).
Conclusion: Nine of the 11 clinical features examined—height, weight, BMD, dentinogenesis imperfecta,
bone deformity, scoliosis, walking ability, fracture rate, and family history—were significantly different
among the three types of OI patients. This finding may be of help in evaluating patients and establishing
their prognosis. [J Formos Med Assoc 2009;108(7):570–576]
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scoliosis
commonly used classification is the one devel-
oped by Sillence et al,5 which classifies OI into
four major types according to different degrees
of phenotypic severity. Type I is the mildest form,
with normal or only slightly affected growth and
minimal bone deformities. Bones start to break
after several months of age. Type II is the most
severe form and is fatal in the perinatal period,
with multiple intrauterine fractures and bone de-
formities of the extremities. Type III is severely
deforming, with fractures often present at birth.
Patients have extremely short stature with pro-
gressive limb and spine deformities secondary to
multiple fractures. Physical activity is restricted and
growth retardation is extremely severe. Type IV 
is the most phenotypically heterogeneous group,
and encompasses all patients who do not meet
the criteria for types I–III. The phenotype can vary
from severe to mild. Recently, type IV has been
further divided into types V, VI and VII, based on
bone architecture and histological characteristics.6
Despite its prevalence, information concern-
ing the clinical features of this genetic disorder 
is lacking in Taiwan. Thus, this study aimed to
characterize the clinical features of OI patients 
in Taiwan, to establish a practical correlation for
distinguishing different clinical subtypes of OI.
Patients and Methods
Subjects
The medical records of 48 patients with OI were
reviewed retrospectively from January 1996 to
June 2008, at Mackay Memorial Hospital, Taipei,
Taiwan.
Assessment
Diagnosis and classification were based on clini-
cal and radiological characteristics, according to
the Sillence classification system.5 Every patient
was reviewed at the clinic by a single author in
person. No patients were classified as OI type II—
we therefore analyzed only three different groups.
For each patient, we recorded height, weight and
bone mineral density (BMD) standard deviation
scores (SDSs), walking ability, annual fracture
rate, family history, and, if present, blue sclera,
DI, hearing loss, bone deformity, and scoliosis.
Height and weight were transformed to SDSs 
on the basis of a standard growth table for the
Taiwanese population.7 BMD was assessed by
dual energy X-ray absorptiometry (DEXA) of the
lumbar spine (L1–L4), using the Hologic QDR
4500 system (Bedford, MA, USA). Since there is a
lack of adequate reference data in Taiwanese
children for BMD assessment using this method,
we used normative reference data taken from the
literature.8,9 The BMD results were converted to
age- and gender-specific SDSs. According to the
classification used by our radiologists, osteopenia
was defined as BMD SDS < −1, and osteoporosis
as BMD SDS < −2. The annual fracture rate was
calculated based on the reports of parents or
medical records. Despite the clinical finding that
pamidronate therapy increases BMD, decreases
fracture rate, and substantially improves func-
tional status for OI patients,10–12 none of these
patients received pamidronate treatment at the
time of assessment.
Statistical analysis
SPSS version 11.5 (SPSS Inc., Chicago, IL, USA)
was used to analyze the clinical and radiological
data among the different subtypes of patients. The
relationship between age and the presence of each
clinical feature of OI types I, III and IV was tested
using Pearson’s correlation, and significance was
tested using Fisher’s r-z transformations. Differ-
ences were considered to be statistically significant
when p was < 0.05.
Results
The clinical characteristics of the 48 participants
are listed in Table 1. There were 33 female and
15 male patients with ages ranging from 2 months
to 53 years. Nineteen patients were classified as
type I, 10 as type III, and 19 as type IV. Height
SDSs were −0.76 ± 0.91 in type I, −9.54 ± 4.36 in
type III, and −3.02 ± 2.70 in type IV. BMD SDSs
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were −3.16 ± 2.00 in type I, −5.35 ± 2.13 in type
III, and −4.19 ± 1.77 in type IV (Table 2). The
clinical feature of blue sclera was present in 89%
of type I patients, 80% of type III, and 58% of
type IV. Eighty percent of type III patients had
DI, in contrast to 5% in type I and 42% in type
IV. Annual fracture rate was 0.8 ± 0.7 in type I pa-
tients, 4.4 ± 0.6 in type III, and 2.0 ± 0.7 in type IV.
In type I patients, 84% had a family history of
OI, compared with none in type III, and 37% in
type IV (Table 3). Among the three subtypes, there
were statistically significant differences (p < 0.05)
in the following clinical features: height SDS,
weight SDS, BMD SDS, DI, bone deformity, sco-
liosis, walking ability, annual fracture rate, and
family history. However, no significant differences
were found in blue sclera (p = 0.075) and hearing
loss (p = 0.832). In OI type I, the presence of bone
deformity was associated with increased age (r =
0.47, p < 0.05). In OI type IV, the presence of
hearing loss was associated with increased age
(r = 0.58, p < 0.05). No other clinical features were
associated with increased age in OI types I, III
and IV (Table 4).
Discussion
In general, there is no reported gender difference
in the incidence of OI. However, we found a pre-
dominance of female patients in our population,
a ratio of 2.2 to 1, a finding similar to that re-
ported by Santili et al.13 Growth retardation is 
an important symptom of OI, and is especially
severe in OI type III.14 Our results in this regard
are similar to those of a national survey of OI pa-
tients in Japan, which reported that height SDSs
were −3.36 ± 3.59, −7.83 ± 3.54, and −4.63 ± 3.13
in types I, III and IV, respectively.15
DEXA is one of the most sensitive methods for
detecting low BMD in children—a condition that
may be missed when using plain radiographs.16
DEXA may help to establish the diagnosis, assess
the prognosis, and possibly monitor the response
to medical treatment. For OI patients, even in
the milder form, decreased BMD can be detected
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Table 3. Clinical characteristics of 48 patients with osteogenesis imperfecta (OI) types I, III and IV
OI type
Blue 
DI
Hearing Bone 
Scoliosis
Walking without Wheelchair Annual Family 
sclera loss deformity aids or devices bound fracture rate history
Type I (n = 19) 89% 5% 11% 16% 26% 100% 0% 0.8 ± 0.7 84%
Type III (n = 10) 80% 80% 10% 100% 100% 0% 100% 4.4 ± 0.6 0%
Type IV (n = 19) 58% 42% 5% 68% 58% 63% 21% 2.0 ± 0.7 37%
p 0.075 0.001 0.832 0.001 0.001 0.001 0.001 0.001 0.001
DI = dentinogenesis imperfecta.
by DEXA.17,18 In our study, all patients showed
reduced BMD, and 81% had osteoporosis.
Blue sclera is a distinctive feature of unknown
etiology in OI.19 Most patients with OI type I
have blue sclera throughout life. In OI types III
and IV, the sclera may also be blue at birth and
during infancy, but the blue color disappears
with time during childhood.20 In our study, the
majority of our patients (75%) presented with
blue sclera.
DI, another important symptom of OI, is 
associated with molecular abnormality of type I
collagen. Discoloration and pulpal obliteration
are the major presentations. The manifestation
of OI with bone fragility is helpful for differen-
tial diagnosis from other fracture conditions in
children, including child abuse. In the study by
Lukinmaa et al,21 DI was not common in OI type
I, but was observed frequently in types III and IV,
a finding in accordance with our results.
Progressive hearing loss is one of the principal
symptoms of OI, and the most common age of
onset is in the second, third, and fourth decades
of life. At the age of 50 years, about half of the
H.Y. Lin, et al
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Table 2. Clinical profiles of 48 patients with osteogenesis imperfecta (OI) types I, III and IV
OI type Sex (M/F) Age range (yr) H (SDS) W (SDS) BMD (SDS)
Type I (n = 19) 5/14 2–48 −0.76 ± 0.91 −0.54 ± 0.87 −3.16 ± 2.00
Type III (n = 10) 4/6 0.2–32 −9.54 ± 4.36 −3.47 ± 1.51 −5.35 ± 2.13
Type IV (n = 19) 6/13 2–53 −3.02 ± 2.70 −0.75 ± 1.28 −4.19 ± 1.77
p 0.001 0.001 0.020
M = male; F = female; H = height; SDS = standard deviation score; W = weight; BMD = bone mineral density.
Table 4. Relationships between age and clinical features of patients with osteogenesis imperfecta types I, III and IV
Clinical features
Type I (n = 19) Type III (n = 10) Type IV (n = 19)
r p r p r p
Blue sclera −0.22 NS −0.57 NS −0.19 NS
DI −0.10 NS −0.18 NS 0.01 NS
Hearing loss 0.42 NS 0.46 NS 0.58 < 0.05
Bone deformity 0.47 < 0.05 Undefined Undefined −0.05 NS
Scoliosis 0.07 NS Undefined Undefined 0.04 NS
Walking without assistance Undefined Undefined Undefined Undefined 0.30 NS
Wheelchair bound Undefined Undefined Undefined Undefined −0.23 NS
Family history 0.08 NS Undefined Undefined 0.41 NS
Annual fracture rate −0.12 NS −0.12 NS 0.40 NS
DI = dentinogenesis imperfecta; NS = not significant.
patients have symptoms of hearing loss.22–25 In
our study, four adult patients (8%) suffered from
hearing loss, and they were aged 29, 31, 48 and
53 years, respectively, at the time of the study.
In patients with OI, deformities are frequently
observed in the long bones, and scoliosis, spinal
deformities, and compression fractures are also
common (Figure). The causes of bone deformi-
ties are imperfect healing after fracture, as well 
as weight bearing itself, without apparent frac-
ture.15 In our study, 54% of patients had bone
deformities.
The pathology of scoliosis is based on verte-
bral fragility, and it deteriorates progressively with
increasing age.26 Karbowski et al27 carried out a
nationwide cross-sectional study for patients with
OI, and reported that scoliosis was observed in
74.5% (76/102) of the subjects, with an average
age of 24.6 years. Engelbert et al28 performed an-
other cross-sectional study, and found that 47%
(22/47) of patients with OI had scoliosis, with a
mean age of 7.7 years. Our data showed that sco-
liosis was presented in 54% (26/48) of patients,
with a mean age of 18.1 years.
A positive family history is useful for the diag-
nosis and classification of OI. It is difficult to dis-
tinguish OI from child abuse in the absence of
affected family members and obvious extraskele-
tal features.29,30 Our study showed that 48% of
patients had a positive family history, which was
similar to that reported by Santili et al (41%).13
Since several clinical features in OI are pro-
gressive (e.g. scoliosis26 and hearing loss22–25). For
these features, we investigated age-related factors.
We found that increased age was associated with
bone deformity and hearing loss in OI types I
and IV, respectively.
OI is a congenital disorder with clinically di-
verse presentations, from minimal symptoms to
perinatal fatality. In this study of 48 patients with
OI, we found that height SDS, weight SDS, BMD
SDS, DI, bone deformity, scoliosis, walking ability,
fracture rate, and family history were significantly
different between types I, III, and IV. Patients
with OI type III had the most severe phenotypes
or the highest incidence of all these nine clinical
features, except family history, which was found
most often in OI type I. Conversely, patients with
OI type I had the mildest phenotypes or the low-
est incidence of the other eight clinical features.
These clinical characteristics may help to evaluate
patients and establish their prognosis.
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Figure. Radiograph of whole spine and lower extremities in case 29, a 32-year-old male patient with osteogenesis 
imperfecta type III. (A) Anteroposterior image of whole spine showing severe thoracolumbar scoliosis. (B) Lateral image
of whole spine showing marked deformity and severe thoracolumbar kyphoscoliosis. (C) Anteroposterior image of lower
extremities showing bowing deformity of bilateral femurs and healed fracture of the proximal third of the right femur.
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